在心肌梗塞后的β-阻塞疗法
Pilar Cataldo Miranda1, Danijela Gasevic2, Caroline Trin1
1School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
JACC. Advances
|January 31, 2025
概括
心肌梗塞 (MI) 后的β-阻断剂治疗显示益处正在减弱,特别是在保留喷射分数的患者中. 需要进一步的研究来确定其在现代MI管理中的作用.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 药物治疗 药物治疗
背景情况:
- 从历史上看,β抑制剂是心肌梗塞 (MI) 后护理的基础,显著降低死亡率和发病率.
- 对心脏病发作患者的治疗策略不断发展,引发了有关贝塔抑制剂治疗的持续普遍益处的问题.
- 目前的证据质疑β-阻断剂在特定患者亚组中的有效性,例如那些左心室喷射分数保存的患者.
研究的目的:
- 从历史到当代实践中,审查和比较有关心肌梗塞 (MI) 的β-阻断剂治疗的主要研究.
- 评估β-阻断剂对各种健康结果的影响,在不断发展的心脏病治疗的背景下.
- 为了确定知识上的差距,并强调需要进一步研究β-阻断剂治疗在MI后管理中的当前作用.
主要方法:
- 有影响力的研究的系统审查和比较分析.
- 包括研究跨越前透时代到现代治疗实践的研究.
- 专注于研究,研究与使用β-阻断剂后的MI相关的各种健康结果.
主要成果:
- 在心脏病发作后,β阻断剂治疗的明显益处在当代治疗中不那么明显.
- 特别是在左心室喷射分数保留的患者中,有效性受到质疑.
- 当代的指导方针显示,在心脏病后患者中使用β-阻断剂的建议有变化.
结论:
- 贝塔抑制剂治疗在心肌梗塞 (MI) 后治疗中的作用需要重新评估.
- 有证据表明,益处可能会下降,特别是在特定患者群体中.
- 进一步的研究至关重要,以建立最佳的,以证据为基础的准则,以使用β-阻断剂在当前的MI护理.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
528
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
528
01:16Antianginal Drugs: Nitrates and β-Blockers
509
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
509
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
404
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
404
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
515
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
515
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375